Library
Fluetonitazene is a benzimidazole derivative which is an opioid designer drug. It was patented in 2024 as a potential novel analgesic, but appeared on the illicit market at around the same time, first being identified in Germany in March 2024. It is a potent opioid agonist in vitro with similar potency to N-Desethyletonitazene.
Also known as: N,N-diethyl-2-[2-[[4-(2-fluoroethoxy)phenyl]methyl]-5-nitro-benzimidazol-1-yl]ethanamine
No route information available yet.
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Substance data is aggregated from the following public harm-reduction and reference sources.
This static page is intended as a readable non-JS and prerender-friendly library export.
Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.
Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu
